Project Management Coordinator: Alexion Pharmaceuticals,Inc.

Responsiblities:

The Project Management Coordinator will provide critical support to the project management team within a global research and development organization. In this capacity the Project Coordinator will be charged with developing, maintaining and disseminating essential project documentation in accordance with company policies and procedures as well as external regulations.

• Assists the Senior Managers/Associate Directors/Directors of Project Management with the creation, implementation and control of multiple global and local drug development projects.
• Creates, maintains and disseminates essential documentation including project timelines, task lists, meeting agendas, meeting minutes, contact lists, budgets and external communications.
• Conducts ongoing data entry and maintenance for multiple internal development program databases.
• Drafts progress and budget reports and presentations for the project management team.
• Schedules and coordinates global and local project team meetings.
• Maintains departmental SOPs and internal processes.
• Assists the Director of Project Management with training and development activities for the department.
• Assist with any special projects as assigned

Requirements

• Bachelor’s degree
• 3 years professional experience, preferably in the pharmaceutical/biotech industry or in healthcare
• Prior project coordination and/or administrative experience preferred
• Superb written and verbal communication skills
• Proficient with Microsoft Office suite (including Project, Word, Excel, Powerpoint)
• Ability to work accurately under tight deadlines. Must be able to plan and manage multiple priorities

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Employing more than 500 people worldwide, Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic and kidney diseases, transplant, cancer, and autoimmune disorders. Soliris^(R) (eculizumab) is Alexion's first marketed product for patients with paroxysmal noctural hemoglobinuria (PNH) a rare, debilitating and life-threatening blood disorder defined by the destruction of red blood cells, or hemolysis. Soliris is approved in the U.S. and Europe in 2007, and Canada and Australia in 2009. Alexion is evaluating other potential indications for Soliris as well as other formulations of eculizumab for additional clinical indications, and is pursuing development of other antibody product candidates in early stages of development.

Alexion offers a highly competitive package of base and incentive compensation, group healthcare coverage, tuition reimbursement, relocation assistance, and a 401(K) plan.

Alexion is an Equal Opportunity/Affirmative Action Employer.